Theratechnologies Q2 2025 Earnings Report

Theratechnologies EPS Results

• Actual EPS: -$0.01
• Consensus EPS: -$0.01
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Theratechnologies Revenue Results

• Actual Revenue: $17,729.00 billion
• Expected Revenue: $24.30 million
• Beat/Miss: Beat by +$17,728.98 billion
• YoY Revenue Growth: N/A

Theratechnologies Announcement Details

• Quarter: Q2 2025
• Date: 7/9/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, July 9, 2025
• Conference Call Time: 8:30AM ET

Theratechnologies (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for people with metabolic and endocrine disorders. Founded in 1996 and headquartered in Montreal, Canada, the company operates under the ticker NASDAQ:THTX and TSX:TH and has established itself through targeted research in hormone regulation and metabolic control.

The company’s lead product, EGRIFTA (tesamorelin for injection), is an FDA-approved growth hormone-releasing factor analog indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In addition to its marketed therapy, Theratechnologies maintains a diversified pipeline with clinical programs such as Tesomet, an investigational drug for hypothalamic obesity and rare metabolic disorders, and ongoing research into novel small molecules aimed at improving lipid and glucose metabolism.

Theratechnologies manages a hybrid operating model combining in-house expertise in clinical development, regulatory affairs and commercial operations with strategic partnerships to expand its reach. The company markets EGRIFTA in the United States and Canada, while collaborating with regional partners in Europe and Latin America to obtain regulatory approvals and facilitate patient access. Manufacturing and distribution agreements ensure consistent supply through specialty pharmacies and hospital networks.

Governed by an experienced leadership team, Theratechnologies is led by President and CEO Michel Ménard, who brings over two decades of pharmaceutical and biotechnology experience. The executive team and board of directors include industry veterans with backgrounds in endocrinology, regulatory strategy and global commercialization, underscoring the company’s commitment to advancing care for patients with complex metabolic needs.